The Michael J. Fox Foundation (MJFF) is sponsoring a US $2 million prize (approx. AUD $2.6M) to the first team to develop a viable selective alpha–synuclein PET tracer and agree to make that tracer available broadly.
Contestants may be MJFF funded or not and can be from either academia or industry.
- Contestants must apply for the prize with pre-clinical and clinical data supporting the broad use of their alpha-synuclein radiotracer. Judges may ask for additional data, including but not limited to raw imaging data.
- The winning contestant must demonstrate that the radiotracer binds with relatively high selectivity to alpha-synuclein according to pre-specified criteria and must demonstrate proof-of-concept in human subjects, including people with Parkinson’s disease and/or another synucleinopathy.
NOTE: All contestants must agree to make the winning radiotracer available for use by The Michael J. Fox Foundation and MJFF awardees through a nonexclusive license or other MJFF-approved mechanism.
- Applications may be submitted at anytime.
- Please contact Research Services to discuss your submission: